Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2017
New UK drug cost rules leave companies fuming
16 March 2017 - British drugmakers on Wednesday accused Theresa May's Conservative government of breaking a manifesto commitment to improve ...
Posted by Michael Wonder on 15 Mar 2017
NICE publishes draft guidance on the use of adalimumab and dexamethasone for uveitis
15 March 2017 - The Department of Health has asked NICE to produce guidance on the use of adalimumab and dexamethasone ...
Posted by Michael Wonder on 15 Mar 2017
Sanofi displeased with NICE decision on rare disease drug
14 March 2017 - French drug major Sanofi and its specialty care global business unit, Sanofi Genzyme, say they are ...
Posted by Michael Wonder on 14 Mar 2017
NICE publishes Appraisal Consultation Document for nivolumab (Opdivo)
14 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of nivolumab in ...
Posted by Michael Wonder on 14 Mar 2017
Future HTA cooperation in Europe
13 March 2017 - Today’s post is written by Davide Ruffo, Government Affairs Senior Manager, Public Affairs & Reimbursement, Eli ...
Posted by Michael Wonder on 06 Mar 2017
NICE publishes draft guidance on the use of etelcalcetide for secondary hyperparathyroidism
3 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of etelcalcetide hydrochloride ...
Posted by Michael Wonder on 03 Mar 2017
The scandal of generic drug pricing: drug regulation policies need review
23 February 2017 - We welcome the news that the Competitions and Market Authority is now taking drug companies such as ...
Posted by Michael Wonder on 02 Mar 2017
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild type mCRC
2 March 2017 - NICE’s recommendation is a significant step forward in Merck’s aspiration to ensure cancer patients have optimal ...
Posted by Michael Wonder on 02 Mar 2017
NICE recommends Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis in England, Wales and Northern Ireland
2 March 2017 - Rapid NICE approval only two months after marketing authorisation in the EU; one of the fastest ...
Posted by Michael Wonder on 02 Mar 2017
NICE says patients accessing more cancer drugs following price drops
2 March 2017 - Patients will have routine access to more cancer drugs as companies have dropped their prices as part ...
Posted by Michael Wonder on 28 Feb 2017
NICE publishes draft guidance on Keytruda
28 February 2017 - The Department of Health has asked NICE to produce guidance on using pembrolizumab in the NHS in ...
Posted by Michael Wonder on 21 Feb 2017
NICE publishes draft guidance for eluxadoline
21 February 2017 - The Department of Health has asked NICE to produce guidance on using eluxadoline in the NHS in ...
Posted by Michael Wonder on 21 Feb 2017
NICE draft guidelines reject Ipsen’s Cabometyx
21 February 2017 - NICE has issued its first draft guidelines on Ipsen's Cabometyx, recommending against the drug's routine use ...
Posted by Michael Wonder on 15 Feb 2017
NICE rejects Alexion’s rare disease therapy Kanuma
15 February 2017 - NICE has published a final evaluation determination rejecting the use of Alexion's Kanuma to treat infants, ...
Posted by Michael Wonder on 15 Feb 2017
NICE publishes draft guidance for Venclyxto
15 February 2017 - The Department of Health has asked NICE to produce guidance on using venetoclax in the NHS in ...